In studies, MPO was strongly associated with an increased risk of coronary artery disease and acute HF, being a promising biomarker of cancer therapy-related cardiotoxicity in BC patients treated with anthracyclines and trastuzumab [20,59,60,61]. This evidence concerns the gene MPO and coronary artery disorder.